Having initially targeted $115m in proceeds, the genome sequencing spinout of Stanford has closed its offering at $140m after a full exercise of the overallotment option.

BlueCross BlueShield Venture Partners, Ascension Ventures and Echo Health Ventures are all set to exit patient management software producer Phreesia, which has raised $109m in VC funding.

Stanford's Atreca floated in the middle of its range and will use the funding to advance its lead cancer immunotherapeutic canadidate through the clinic.

GSK-backed Atreca floated in the middle of its range and will use the funding to advance its lead cancer immunotherapeutic canadidate through the clinic.

The gene therapy developer has boosted its initial public offering, which gave an exit to Alexandria Real Estate Equities, to more than $163m in size.

The SoftBank, Comcast and Alphabet-backed communication platform developer saw its shares pop and its market cap climb nearly 50% to $19.5bn following its direct listing.

The AbbVie Ventures-backed neurodegenerative disease treatment developer floated in the middle of its range having previously raised $129m in funding.

The Alexandria Venture Investments-backed genetic disease therapy developer is floating above its range having increased the number of shares in the offering.

Alphabet, Telstra and RackSpace-backed endpoint cybersecurity technology producer CrowdStrike will float above a range it had already increased.

CyberAgent, GMO, Japan Post, Nikkei, Nippon Life, Recruit and Salesforce-backed Sansan priced its shares at the top of its range today and will raise $360m including the over-allotment option.